Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer - Authors' reply

FUS inactivation promotes leptomeningeal metastasis of lung cancer through the up-regulation of CD36.

Science translational medicine·2026

Pathological Response, Tumor Microenvironment Dynamics, and Survival Dissociation after Neoadjuvant Chemoimmunotherapy for Lung Cancer with Rare Histological Subtypes.

Annals of surgical oncology·2026

Comparison of circulating tumor DNA assays for molecular residual disease detection in non-small cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in China.

EClinicalMedicine·2026

Survival outcomes and molecular predictors in small cell lung cancer with brain metastases receiving immunotherapy.

Journal of neuro-oncology·2026

Cardiovascular adverse events in non-small cell lung cancer patients receiving osimertinib therapy: a systematic review and meta-analysis.

Lung cancer (Amsterdam, Netherlands)·2026

Challenges in the use of the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer.

The Lancet. Oncology·2026

Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.

The Lancet. Oncology·2026

Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.

The Lancet. Oncology·2026

Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial.

The Lancet. Oncology·2026

High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial.

The Lancet. Oncology·2026

SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial.

The Lancet. Oncology·2026

Identifying Patients With Prostate Cancer Who Benefit Most From Routine Cardiovascular Specialist Referral.

JACC. CardioOncology·2026

Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission: a long-term follow-up of the randomized RIVETING trial.

Crohn's & colitis 360·2026

Unrecognized Charcot-Marie-Tooth Disease Unmasked by Chemotherapy-Induced Neurotoxicity.

Cureus·2026

Intraoperative Hemodynamic Management and Cerebral Protection During Awake Craniotomy: Evidence-Based Approaches.

Anesthesiology research and practice·2026

Combined Enzyme-Responsive Nano-Peptide Drug with Photothermal Function for Effective Anti-Hepatocellular Carcinoma in Mice Model.

International journal of nanomedicine·2026

Pathologic Complete Response to Neoadjuvant Dual Checkpoint Blockade with Durvalumab Plus Tremelimumab in Advanced-Stage HCC: A Case Report.

Journal of hepatocellular carcinoma·2026

Related Experiment Videos

Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer - Authors' reply

Related Concept Videos

FUS inactivation promotes leptomeningeal metastasis of lung cancer through the up-regulation of CD36.

Pathological Response, Tumor Microenvironment Dynamics, and Survival Dissociation after Neoadjuvant Chemoimmunotherapy for Lung Cancer with Rare Histological Subtypes.

Comparison of circulating tumor DNA assays for molecular residual disease detection in non-small cell lung cancer.

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in China.

Survival outcomes and molecular predictors in small cell lung cancer with brain metastases receiving immunotherapy.

Cardiovascular adverse events in non-small cell lung cancer patients receiving osimertinib therapy: a systematic review and meta-analysis.

Challenges in the use of the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer.

Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.

Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.

Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial.

High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial.

SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial.

Identifying Patients With Prostate Cancer Who Benefit Most From Routine Cardiovascular Specialist Referral.

Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission: a long-term follow-up of the randomized RIVETING trial.

Unrecognized Charcot-Marie-Tooth Disease Unmasked by Chemotherapy-Induced Neurotoxicity.

Intraoperative Hemodynamic Management and Cerebral Protection During Awake Craniotomy: Evidence-Based Approaches.

Combined Enzyme-Responsive Nano-Peptide Drug with Photothermal Function for Effective Anti-Hepatocellular Carcinoma in Mice Model.

Pathologic Complete Response to Neoadjuvant Dual Checkpoint Blockade with Durvalumab Plus Tremelimumab in Advanced-Stage HCC: A Case Report.

Related Experiment Videos

Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer - Authors' reply

Related Concept Videos

Related Articles